IXHL - Incannex Reports Positive Phase 2 Psi-GAD1 Clinical Trial Topline Results

2024-02-28 08:03:13 ET

DENVER, Colo., Feb 28, 2024 ( 247marketnews.com )- Incannex Healthcare Inc. (NASDAQ: IXHL ) reported, this morning, positive topline results from its psilocybin in generalized anxiety disorder (GAD) Phase 2 Psi-GAD1 clinical trial, and that the trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group, the high

Incannex Healthcare is trading at $9.22, up $5.00 (+118.48%), on trading volume of 1,068,021 shares. The only resistance between here and a potential new 52-week high are two daily price spikes.

“We are thrilled with the results from our initial PsiGAD trial,” said President and CEO Joel Latham. “This is the first time psilocybin has been investigated for treatment of generalised anxiety disorder, and the reduction in HAM-A scores we have observed are far greater those reported from trials on established medicines for treatment of anxiety. The improvement in anxiety scores in PsiGAD1 are of a similar magnitude to the change seen in studies investigating psilocybin for treatment of depression disorders. Safety is a key component of any new therapy, and we are delighted that no serious or severe adverse events were observed in PsiGAD patients, which is testament to the focus on safety within the PsiGAD treatment protocol. The safety and efficacy results from PsiGAD1 implore us to continue the development of PsiGAD through large scale well-controlled trials, because this treatment method has the potential to improve the quality of life for millions of people suffering from generalised anxiety disorder.”

The post Incannex Reports Positive Phase 2 Psi-GAD1 Clinical Trial Topline Results first appeared on 24/7 MarketNews .

For further details see: